If you cannot read this message, click here.
     DDNews Top 5 Cancer Stories
       FEBRUARY 2015
From DDNews Daily News:
Array, Novartis ink agreement for encorafenib
By Kelsey Kaustinen, DDNews Senior Editor
Array will acquire worldwide rights to Novartis' Phase 3 BRAF inhibitor

From our February 2015 issue:
Roche teams with Foundation Medicine
By Lloyd Dunlap, DDNews Managing Editor
Molecular information collaboration leverages companies' strengths to advance progress of personalized treatments for oncology

From our February 2015 issue:
Real talk on RASAL2
By Kelsey Kaustinen, DDNews Senior Editor
GIS study finds RASAL2 to be upregulated in triple-negative or estrogen receptor-negative breast cancer tumors

From DDNews Online:
Top 5 for the big C
By Lloyd Dunlap, DDNews Managing Editor
Cegedim Strategic Data tallies cancer treatments in the top 5 European countries

From DDNews Online:
Two advances in glioblastoma
By Lloyd Dunlap, DDNews Managing Editor
Cellectar Biosciences Inc., announces proof-of-principle study of a new class of fluorescent alkylphosphocholine analogs for fluorescence-guided glioma surgery while RestorGenex Corp. presented scientific data on RES-529 for the treatment of GBM
Facebook Facebook
CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600 | Fax: 440-331-7563
©2015 Old River Publications LLC. All Rights Reserved.
Web site designed and managed by Offenberger & White, Inc..
If you no longer wish to receive DDNews mailings, please unsubscribe here.